Announced Mon, 8 Sept · 14:05 IST

Commencement of Commercial Production at IV Fluid Infusion Plant

Regulatory Product ApprovalBusiness Updates View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Sanjivani Paranteral Ltd's subsidiary, SPL Infusion Pvt. Ltd., has started commercial production at its newly set up IV Fluid Infusion Plant in Pune, Maharashtra, effective 6th September 2025. The facility received the necessary manufacturing license from regulatory authorities before commencing operations. The plant is strategically located near major pharmaceutical clusters and hospitals, enabling the company to serve both domestic and export markets. The facility features modern plant and machinery along with solar panels aimed at lowering long-term operating costs. The company describes this as a key milestone that opens a new revenue vertical and strengthens its position in pharmaceutical manufacturing.

Likely market impact

Positive for shareholders as it signals entry into a new revenue stream and expanded manufacturing capacity, though actual financial contribution will depend on how quickly the plant ramps up utilisation and secures customers.